- Home
- LMB vs SNDX Comparison
LMB vs SNDX Comparison
Compare LMB & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- SNDX
- Stock Information
- Founded
- LMB 1901
- SNDX 2005
- Country
- LMB United States
- SNDX United States
- Employees
- LMB N/A
- SNDX N/A
- Industry
- LMB Engineering & Construction
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- SNDX Health Care
- Exchange
- LMB Nasdaq
- SNDX Nasdaq
- Market Cap
- LMB 1.1B
- SNDX 1.2B
- IPO Year
- LMB 2014
- SNDX 2016
- Fundamental
- Price
- LMB $100.65
- SNDX $14.63
- Analyst Decision
- LMB Strong Buy
- SNDX Strong Buy
- Analyst Count
- LMB 3
- SNDX 10
- Target Price
- LMB $115.00
- SNDX $36.20
- AVG Volume (30 Days)
- LMB 216.5K
- SNDX 2.1M
- Earning Date
- LMB 03-12-2025
- SNDX 02-25-2025
- Dividend Yield
- LMB N/A
- SNDX N/A
- EPS Growth
- LMB 29.01
- SNDX N/A
- EPS
- LMB 2.18
- SNDX N/A
- Revenue
- LMB $517,822,000.00
- SNDX $16,000,000.00
- Revenue This Year
- LMB $2.59
- SNDX N/A
- Revenue Next Year
- LMB $12.46
- SNDX N/A
- P/E Ratio
- LMB $44.29
- SNDX N/A
- Revenue Growth
- LMB 0.13
- SNDX N/A
- 52 Week Low
- LMB $38.03
- SNDX $12.06
- 52 Week High
- LMB $107.00
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- LMB 44.58
- SNDX 57.25
- Support Level
- LMB $86.19
- SNDX $13.61
- Resistance Level
- LMB $101.65
- SNDX $14.62
- Average True Range (ATR)
- LMB 6.65
- SNDX 0.62
- MACD
- LMB -0.82
- SNDX 0.15
- Stochastic Oscillator
- LMB 19.74
- SNDX 91.20
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.